Deal reviews fail when managers mistake activity for insight. Here's how to ask the questions that surface real obstacles and accelerate closes.
Your deal review looks like this: you pull the pipeline report, your AE walks through the deals, everyone nods, meeting ends. Three weeks later you miss forecast because a deal you marked "90% confident" stalls in legal review, or the champion who said "I'll champion this" went silent, or no one ever actually verified that the economic buyer knows your solution exists.
Deal reviews that change deals require a different structure. You're not validating the rep's forecast number. You're excavating the obstacles between here and cash, testing the rep's real knowledge of the account, and identifying where you (the manager) actually need to do something.
Theatre deal reviews follow the rep's narrative. The rep presents a deal as progressing, you ask "So we're still on for close in Q3?" and move on. No obstacles surface because the rep doesn't surface them—why would they, if they're being graded on optimism?
Diagnosis deal reviews bypass the narrative and ask about the structure of the deal itself. You're not asking "Where are we?" You're asking "Who decides? Do they know us? What changes their mind?" Those questions force both you and the rep to see what's actually there.
The difference feels small but it's the difference between guessing at forecast and knowing it. Theatre reviews produce surprises in the final week. Diagnostic reviews produce closed deals because obstacles surface early.
Start here: on a deal above a certain size, ask your rep to name everyone who will touch the decision. Not "key stakeholders"—everyone. The person who'll audit the contract. The operations leader who'll implement. The CFO's analyst who'll model the cost. The legal team.
Then ask: which of these people have we actually spoken to?
Most deal reviews skip this. The rep says "The CFO is championing us" and you move on. But until you know whether the implementation lead knows your solution exists, whether legal has seen the contract, whether the CFO's analyst actually ran the numbers, you don't know whether the deal will close. You know the rep thinks it will.
The buying committee map isn't nice-to-have intel. It's the skeleton of the deal. If you can't name everyone who votes, you don't actually have a deal yet.
The economic buyer—the person who owns the budget and lives with the consequences—is where most forecasts break. A rep can have built rapport with five people and still have zero relationship with the person who actually owns the money.
Ask directly: "Who is the economic buyer?" If the rep hesitates, or names someone three levels down, you have a problem. If the rep can name them but hasn't met them, you have a different problem—and a clear task for the next week.
The economic buyer is the only forecast-relevant signal you need. If they know you exist, they've seen a business case, and they've expressed interest in moving forward, the deal is real. If any of those three things is missing, the deal isn't real yet, no matter how confident the rep feels.
Ask your rep to walk you through the last conversation they had with the account. Not the pitch they plan to give—the last real call or email thread. What did you actually learn about how they buy, what they're trying to solve, what worries them?
Most reps can't do this clearly. They jump to "They're very interested" or "They want a demo next week." But "We asked them what happens if they don't solve this, and they said they'll miss their compliance deadline" is a different animal. That's insight you can hold onto.
If the rep can't remember the actual shape of the conversation, they don't know the deal. A deal review that doesn't surface this is just nodding along while your rep guesses.
Every deal above a certain complexity has one core obstacle. It's the thing that, if it doesn't move, the deal doesn't close. It might be budget. It might be internal alignment. It might be a technical proof-of-concept that needs to pass.
Ask your rep: "What's the one thing that has to happen for this to close?"
Then ask: "What would the other side say that is?"
If the rep's answers don't match, the rep doesn't actually understand the obstacle. They're selling their idea of what matters instead of selling to what actually matters. That's where deals die.
The deal review isn't successful because the rep feels heard. It's successful because you—the manager—are now going to take an action the rep can't take alone.
That might be: you call the economic buyer to build relationship. You bring in a technical expert to answer a specific question. You get legal involved early instead of late. You position the deal differently in your executive forecast.
If a deal review doesn't end with a clear task for you, it wasn't a review. It was an update.
Write down the task. Add it to your calendar. Track whether it happened. The rep will notice that deal reviews now matter, and they'll start prepping differently—which means the information you get will actually improve.
Most teams run them weekly for large deals, but the right cadence depends on your deal cycle length and AE experience. A deal with a 6-month cycle might need weekly reviews; a fast-closing SMB deal might only need one when it enters the final stage. The key is reviewing before deals stall, not after.
Move it to the right stage or off the forecast. It's not a failure—it's a success. You just prevented a surprise in the final week. The rep should re-qualify the account, focus on building the economic buyer relationship, or move to a different prospect. Bad news early is better than bad news late.
Separate the deal review from performance review. You're diagnosing obstacles, not judging the rep. Phrase questions neutrally: 'What has the economic buyer said about budget?' instead of 'Have you qualified the budget?' Make it clear the review exists to unblock deals, not to catch people out.
Any deal where the AE isn't certain of close by a specific date. Generally, for enterprise AEs that means deals over $50k ACV; for mid-market, anything above a few months of quota. The threshold matters less than the principle: review when real money and real uncertainty intersect.
Part of our guide to MEDDPICC.
Repwing listens to your discovery calls and puts the next question on your phone while you are still in the conversation. Fourteen days free, no card.
Start free trial